Established in 2006, Genocea originally focused on vaccines. It went public in 2014 and at one point saw its shares soar above $150.
But in 2017, just as the company was poised to begin a Phase 3 trial of an immunotherapy for herpes, Genocea announced that it was switching gears. The company ended its work on infectious diseases and instead began to focus on cancer, using its neoantigen technology designed to create personalized immunotherapies.
